{"id":"W4386725951","doi":"10.1158/2159-8290.cd-23-0436","title":"Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial","year":2023,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"Pharmacyclics; Genentech; Novocure; Amgen; Aeglea BioTherapeutics; Regeneron Pharmaceuticals; Pfizer; Agios Pharmaceuticals; Society for Immunotherapy of Cancer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Oncology; Immune system; Internal medicine; Lung cancer; Clinical endpoint; Surgical oncology; Cancer; Immunotherapy; Clinical trial; Cancer research; Immunology; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006109047,0.0003462732,0.000763775,0.0002249003,0.0004041046,0.00009697889,0.0003193113,0.000167955,0.000654357],"category_scores_gemma":[0.00005084111,0.0002001786,0.0001705155,0.001390838,0.0003237998,0.0004340971,0.0001628117,0.000411559,0.000005035403],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001382072,"about_ca_system_score_gemma":0.002877271,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.0095526,"about_ca_topic_score_gemma":0.01842864,"domain_scores_codex":[0.9975278,0.00006053475,0.0006336705,0.000512469,0.0005154086,0.0007501121],"domain_scores_gemma":[0.9987546,0.0002018126,0.0002708884,0.000588305,0.00007636597,0.0001080727],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8863462,0.001612317,0.002180088,0.0002182131,0.001202972,0.0003460371,0.003745144,0.0003794625,0.02797404,0.00003483363,0.04450713,0.0314536],"study_design_scores_gemma":[0.7920163,0.02041702,0.01349628,0.002307889,0.0007275713,0.0001283887,0.004225931,0.004247242,0.01087603,0.00002866255,0.1505576,0.0009711401],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865675,0.002957633,0.00003261086,0.004814298,0.001916876,0.002658217,0.0003738872,0.00009709172,0.0005819016],"genre_scores_gemma":[0.9781293,0.005437302,0.00001885339,0.001948428,0.0007121678,0.001553677,0.0001933261,0.00008487708,0.01192208],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1060505,"threshold_uncertainty_score":0.9994825,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06199818663256833,"score_gpt":0.3770023694520501,"score_spread":0.3150041828194818,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}